Table 3.
Consequences of sE-cad presence
| Result | System | sE-cad source | Mechanism (if known) | Ref. |
|---|---|---|---|---|
|
| ||||
| Disruption of adherens junctions | Ovarian cancer cell line | Recombinant, Fc fusion | (27) | |
| Mouse mammary tumor cells | Antibody affinity chromatography | (12) | ||
|
| ||||
| Disruption of anti-viral function | Peripheral blood mononuclear cells from HIV patients | Recombinant sE-cad | Abrogation of IFN-gamma response | (73) |
|
| ||||
| Disruption of cell aggregation | Pancreatic cancer cell line | Immunodepletion | (20) | |
| Canine kidney cell line | Immunodepletion | (31) | ||
|
| ||||
| Invasion | Ovarian cancer cell line | Recombinant, Fc fusion | (30) | |
| Pancreatic cancer cell line | Immunodepletion | (20) | ||
| Lung cancer cells | Immunodepletion; HAV peptide | Induction of MMP-2, 9, 14 | (98) | |
| Canine kidney cells | Immunodepletion | (31) | ||
|
| ||||
| Proliferation | Breast cancer cells | Recombinant, Fc fusion | HER2/HER3 phosphorylation | (16) |
|
| ||||
| Signaling | Breast cancer cells | Endogenous; Recombinant, Fc fusion | Binding to HER2/HER3 ERK signaling | (16) |
| Canine kidney cells | Recombinant, myc tag | pERK/pAKT via EGFR | (99) | |
| Peripheral blood mononuclear cell from HIV patients | Recombinant sE-cad | KLRG1 ligation | (73) | |
|
| ||||
| Survival | Canine kidney cells | Recombinant, myc tag | EGFR signaling | (99) |